WST
NYSE · Life Sciences Tools & Services
West Pharmaceutical Services
$375.65
+5.21 (+1.41%)
Financial Highlights (FY 2026)
Revenue
3.00B
Net Income
481.37M
Gross Margin
35.9%
Profit Margin
16.1%
Rev Growth
+2.1%
D/E Ratio
0.07
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 35.9% | 35.9% | 47.2% | 47.2% |
| Operating Margin | 19.0% | 17.1% | 7.3% | 7.1% |
| Profit Margin | 16.1% | 15.3% | 6.4% | 6.7% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 3.00B | 2.94B | 18.07B | 16.48B |
| Gross Profit | 1.08B | 1.05B | 8.53B | 7.78B |
| Operating Income | 570.39M | 502.70M | 1.32B | 1.17B |
| Net Income | 481.37M | 424.24M | 1.16B | 1.11B |
| Gross Margin | 35.9% | 35.9% | 47.2% | 47.2% |
| Operating Margin | 19.0% | 17.1% | 7.3% | 7.1% |
| Profit Margin | 16.1% | 15.3% | 6.4% | 6.7% |
| Rev Growth | +2.1% | +2.1% | +19.9% | -3.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 807.10M | 807.10M | 6.90B | 6.72B |
| Total Equity | 12.32B | 12.32B | 10.56B | 10.04B |
| D/E Ratio | 0.07 | 0.07 | 0.65 | 0.67 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 570.49M | 530.71M | 1.64B | 1.42B |
| Free Cash Flow | — | — | 1.22B | 695.16M |